Biden Admin Proposes CMS Rule to Make Drug Manufacturing Costs Transparent

The Biden administration and the Centers for Medicare and Medicaid Services (CMS) have put forward a new rule intended to bolster drug price transparency by highlighting drug manufacturing and transportation costs. This would be performed via a variety of tools, including a drug price verification survey that would be issued when new drugs are priced or existing drugs see price hikes.

According to Zachary Brennan, “The survey would come as CMS acknowledges the fact that there currently isn’t a centralized collection of specific data from manufacturers (or wholesalers) used by CMS to verify prices that manufacturers report. But CMS also made clear it won’t be using the survey data to further assess either the clinical or cost effectiveness of the drugs reviewed.”

To read more, click here.

(Source: Endpoints News, May 24^th, 2023)